These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 30805731)
1. Cost-effectiveness of newborn screening for severe combined immunodeficiency. Van der Ploeg CPB; Blom M; Bredius RGM; van der Burg M; Schielen PCJI; Verkerk PH; Van den Akker-van Marle ME Eur J Pediatr; 2019 May; 178(5):721-729. PubMed ID: 30805731 [TBL] [Abstract][Full Text] [Related]
2. Systematic neonatal screening for severe combined immunodeficiency and severe T-cell lymphopenia: Analysis of cost-effectiveness based on French real field data. Clément MC; Mahlaoui N; Mignot C; Le Bihan C; Rabetrano H; Hoang L; Neven B; Moshous D; Cavazzana M; Blanche S; Fischer A; Audrain M; Durand-Zaleski I J Allergy Clin Immunol; 2015 Jun; 135(6):1589-93. PubMed ID: 25840725 [TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness/Cost-Benefit Analysis of Newborn Screening for Severe Combined Immune Deficiency in Washington State. Ding Y; Thompson JD; Kobrynski L; Ojodu J; Zarbalian G; Grosse SD J Pediatr; 2016 May; 172():127-35. PubMed ID: 26876279 [TBL] [Abstract][Full Text] [Related]
4. A Markov model to analyze cost-effectiveness of screening for severe combined immunodeficiency (SCID). Chan K; Davis J; Pai SY; Bonilla FA; Puck JM; Apkon M Mol Genet Metab; 2011 Nov; 104(3):383-9. PubMed ID: 21810544 [TBL] [Abstract][Full Text] [Related]
5. Potential costs and benefits of newborn screening for severe combined immunodeficiency. McGhee SA; Stiehm ER; McCabe ER J Pediatr; 2005 Nov; 147(5):603-8. PubMed ID: 16291349 [TBL] [Abstract][Full Text] [Related]
6. Clinical and economic aspects of newborn screening for severe combined immunodeficiency: DEPISTREC study results. Thomas C; Durand-Zaleski I; Frenkiel J; Mirallié S; Léger A; Cheillan D; Picard C; Mahlaoui N; Riche VP; Roussey M; Sébille V; Rabetrano H; Dert C; Fischer A; Audrain M Clin Immunol; 2019 May; 202():33-39. PubMed ID: 30946917 [TBL] [Abstract][Full Text] [Related]
7. Newborn screening for severe combined immune deficiency (technical and political aspects). Kobrynski L Curr Opin Allergy Clin Immunol; 2015 Dec; 15(6):539-46. PubMed ID: 26485096 [TBL] [Abstract][Full Text] [Related]
8. Systematic evidence review of newborn screening and treatment of severe combined immunodeficiency. Lipstein EA; Vorono S; Browning MF; Green NS; Kemper AR; Knapp AA; Prosser LA; Perrin JM Pediatrics; 2010 May; 125(5):e1226-35. PubMed ID: 20403930 [TBL] [Abstract][Full Text] [Related]
9. The case for severe combined immunodeficiency (SCID) and T cell lymphopenia newborn screening: saving lives…one at a time. Quinn J; Orange JS; Modell V; Modell F Immunol Res; 2020 Feb; 68(1):48-53. PubMed ID: 32128663 [TBL] [Abstract][Full Text] [Related]
10. Societal value of newborn screening for severe combined immune deficiency in Arkansas: An economic analysis. Hays LH Public Health Nurs; 2019 Jul; 36(4):541-544. PubMed ID: 30945355 [TBL] [Abstract][Full Text] [Related]
11. Fiscal implications of newborn screening in the diagnosis of severe combined immunodeficiency. Kubiak C; Jyonouchi S; Kuo C; Garcia-Lloret M; Dorsey MJ; Sleasman J; Zbrozek AS; Perez EE J Allergy Clin Immunol Pract; 2014; 2(6):697-702. PubMed ID: 25439359 [TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of pulse oximetry screening for critical congenital heart defects following homebirth and early discharge. Narayen IC; Te Pas AB; Blom NA; van den Akker-van Marle ME Eur J Pediatr; 2019 Jan; 178(1):97-103. PubMed ID: 30334077 [TBL] [Abstract][Full Text] [Related]
13. [Neonatal screening of severe combined immunodeficiencies]. Thomas C; Mirallié S; Pierres C; Dert C; Clément MC; Mahlaoui N; Durand-Zaleski I; Fischer A; Audrain M; Arch Pediatr; 2015 Jun; 22(6):646-52. PubMed ID: 25896629 [TBL] [Abstract][Full Text] [Related]
14. Newborn screening for severe combined immunodeficiency: clinical and cost-effectiveness approaches. Boyarchuk O; Yarema N; Kinash M; Chornomydz I Pol Merkur Lekarski; 2021 Feb; 49(289):80-83. PubMed ID: 33713100 [TBL] [Abstract][Full Text] [Related]
15. Overview of 15-year severe combined immunodeficiency in the Netherlands: towards newborn blood spot screening. de Pagter AP; Bredius RG; Kuijpers TW; Tramper J; van der Burg M; van Montfrans J; Driessen GJ; Eur J Pediatr; 2015 Sep; 174(9):1183-8. PubMed ID: 25875249 [TBL] [Abstract][Full Text] [Related]
16. A Cost-Effectiveness Analysis of Newborn Screening for Severe Combined Immunodeficiency in the UK. Bessey A; Chilcott J; Leaviss J; de la Cruz C; Wong R Int J Neonatal Screen; 2019 Sep; 5(3):28. PubMed ID: 33072987 [TBL] [Abstract][Full Text] [Related]
17. An analysis and decision tool to measure cost benefit of newborn screening for severe combined immunodeficiency (SCID) and related T-cell lymphopenia. Modell V; Knaus M; Modell F Immunol Res; 2014 Oct; 60(1):145-52. PubMed ID: 24599744 [TBL] [Abstract][Full Text] [Related]
18. The cost-effectiveness of expanding newborn screening for up to 21 inherited metabolic disorders using tandem mass spectrometry: results from a decision-analytic model. Cipriano LE; Rupar CA; Zaric GS Value Health; 2007; 10(2):83-97. PubMed ID: 17391418 [TBL] [Abstract][Full Text] [Related]
19. The inclusion of ADA-SCID in expanded newborn screening by tandem mass spectrometry. la Marca G; Giocaliere E; Malvagia S; Funghini S; Ombrone D; Della Bona ML; Canessa C; Lippi F; Romano F; Guerrini R; Resti M; Azzari C J Pharm Biomed Anal; 2014 Jan; 88():201-6. PubMed ID: 24076575 [TBL] [Abstract][Full Text] [Related]